RecruitingNCT06608823

ARTIST

ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

JenaValve Technology, Inc.Multiple US sitesView on ClinicalTrials.gov

AI Description

To demonstrate non-inferiority of the Trilogy Transcatheter Heart Valve (THV) System compared with surgical aortic valve replacement (SAVR) for treatment of subjects with clinically significant native aortic regurgitation (AR)

Report inaccurate information

Who can join
child, adult, older adult
Participants
1016
Expected completion
2036-02
Funded by
industry

Conditions studied

Aortic Insufficiency, Aortic Regurgitation, Aortic Valve Insufficiency

What is being tested

  • DEVICE: SAVR
  • DEVICE: Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System

What it measures

  • All stroke, Number of patients that had stroke, 12 months
  • All-Cause Mortality, all-cause mortality at 12 months, 12 months
  • unplanned cardiac rehospitalization, Number of patients who had unplanned cardiac rehospitalization, 12 months

Centers Participating

These centers are participating in this study. Reach out to them directly to learn more.

Data Sources and Methodology

Registry entry updated 2026-09-17

Deciding whether to join a study is your choice, and you can ask a study team questions before you decide anything.

If you would rather we did it with you, call us on (656) 206-4686.